BOUNDLESS BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.12 USD | +6.67% |
|
-19.36% | -.--% |
| Apr. 22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
| Apr. 22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 202.9 | - | - |
| Enterprise Value (EV) 1 | 172.2 | 166.7 | 101.8 |
| P/E ratio | -2.72 x | -2.45 x | -2.34 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -2.37 x | -1.53 x | -0.65 x |
| EV / FCF | -3.19 x | -2.38 x | -1.14 x |
| FCF Yield | -31.4% | -42% | -87.4% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 22,253 | - | - |
| Reference price 2 | 9.120 | 9.120 | 9.120 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA 1 | - | -72.68 | -109 | -156.4 |
| EBIT 1 | - | -73.72 | -99.89 | -126.8 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -71.95 | -93.82 | -110.6 |
| Net income 1 | -49.43 | -68.13 | -94.64 | -123.5 |
| Net margin | - | - | - | - |
| EPS 2 | -2.080 | -3.353 | -3.720 | -3.890 |
| Free Cash Flow 1 | - | -54 | -70 | -89 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Announcement Date | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -16.88 | -17.25 | -18.9 | -19.91 | -22.3 | -22.9 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -15.43 | -17.45 | -18.7 | -19.55 | -21.1 | -22.65 |
| Net income 1 | -15.43 | -16.87 | -18.03 | -18.8 | -21.1 | -22.65 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -12.27 | -0.7333 | -0.7733 | -0.7967 | -0.8900 | -1.000 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 30.7 | 36.3 | 101 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -54 | -70 | -89 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 0.4 | 0.5 | 0.5 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/6/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.12
USD
Average target price
23
USD
Spread / Average Target
+152.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 190M | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
- Stock Market
- Equities
- BOLD Stock
- Financials Boundless Bio, Inc.
